^
Association details:
| Biomarker: | EGFR mutation + GRM8 mutation |
|---|---|
| Cancer: | Lung Non-Small Cell Squamous Cancer |
| Drug Class: | EGFR inhibitor + Tyrosine kinase inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1215P - EGFR-mutated squamous cell lung cancer and its association with outcomes
Published date:
09/12/2021
Excerpt:
We consecutively enrolled stage IV, EGFR-mutant-, and EGFR-TKI-treated patients with SCC....Among the patients with EGFR mutations, shorter progression-free survival (PFS) was observed in SCC compared to adenocarcinoma (4.6 vs. 11.0 months, P<0.001)…Further exploration of EGFR-mutant SCC revealed...Mutations in GRM8 (P=0.025) were associated with improved PFS.
